![]()
|
|
||||||||
J. Biol. Chem., Vol. 278, Issue 15, 13159-13165, April 11, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, December 4, 2002, and in revised form, January 12, 2003
Carnitine acyltransferases are a family of
ubiquitous enzymes that play a pivotal role in cellular energy
metabolism. We report here the x-ray structure of human carnitine
acetyltransferase to a 1.6-Å resolution. This structure reveals
a monomeric protein of two equally sized In eukaryotic cells, the carnitine system plays a vital role in
fatty acid Arguably, the most critical member is CPT I, which is responsible for
facilitating the transfer of long chain fatty acids into the
mitochondria. There are two different types of CPT I in mammalian
tissues (1), a liver (L-CPT I) and a muscle isoform (M-CPT I). Both
isoforms of CPT I are inhibited by malonyl-CoA, which is the committed
intermediate for the biosynthesis of fatty acids. However, each isoform
displays a different sensitivity to this metabolite. Malonyl-CoA
inhibition regulates and balances However, the lack of a molecular structure for any member of this
family has hampered our understanding of the biology of these enzymes
and the rational design of selective inhibitors. Here we report the
x-ray crystal structure of human peroxisomal carnitine
acetyltransferase (hpCAT), which represents the first structure for the
carnitine acyltransferase family (Table
I). To gain more insight into the
function of hpCAT, we have also modeled the binding sites of carnitine
and CoA using the superimposition of the ternary substrate complex of a
structurally and functionally related protein, dihydrolipoyl
trans-acetylase (E2p). The results from this work correlate well with
previous experimental data and provide further information regarding
the catalytic mechanism of hpCAT and ligand binding sites.
Crystallization--
Production, purification, and
crystallization of hpCAT were performed as described previously (10)
with the exception that selenomethionine was also incorporated into
hpCAT, was crystallized, and was used for multi-wavelength anomalous
dispersion (MAD) phasing. The crystals belong to orthorhombic space
group P212121, and its unit cell
parameters are a = 137.72, b = 84.77, c = 57.86 with one molecule in the crystallographic
asymmetric unit.
Data Collection--
All of the x-ray diffraction data were
collected at 100 K. Before flash-freezing, the crystals were dipped in
the crystallization reservoir solution to which 15% polyethylene
glycol 8000 and 40% glycerol had been added. The MAD data sets were
collected from a single selenomethionine crystal at the Cornell High
Energy Synchrotron Source F-2 beamline using the ADSC Quantum-4 CCD
detector system (Table I). The native data set were collected from a
single crystal using an "in-house" R-AXIS IV++ image plate system
with Osmic mirrors and a Riguku HU-H3R CU rotating anode generator
(Table I). All of the diffraction images were indexed, integrated, and scaled by the HKL2000 suite programs DENZO and SCALEPACK (11).
MAD Phasing--
The conventional direct methods programs SHAKE
and BAKE (SnB) and SHELXS97 (12, 13) were used to initially locate 18 selenium atom sites. The CNS software suite, version 1.1, was then used to refine the initial sites located by SnB and to identify four additional selenium sites (14). The selenomethionine diffraction data
were then phased, and the solvent was flattened using CNS to produce an
interpretable electron density map to a 1.6-Å resolution. The initial
figure of merit of 0.49 was improved to 0.97 after density
modification. The correct handedness of the selenium atom model was
determined by careful inspection of electron density maps.
Model Building and Structure Refinement--
Initial model
building was carried out using the auto-tracing program MAID (15),
which assigned 250 residues in hpCAT. Model building was further
carried out using the graphics program O (16).
The refinement of the structure was performed with CNS (14). The model
was refined with CNS against MAD data in cycles of simulated annealing,
positional, and individual B-factor refinement and alternated with
interactive rebuilding with the program O. Once the model was at a
reasonable quality as judged by refinement statistics, refinement was
continued against the 1.6-Å native data set. Further cycles of
refinement and model building were carried out until the
Rfactor and Rfree
converged to 0.208 and 0.232, respectively. 5% reflections were
selected randomly and excluded from the refinement procedure (17).
Solvent water molecules were assigned from difference Fourier maps by
the use of the automated scripts implemented in CNS. At present, the
model has been built from residue 9 to 599, and 472 solvent molecules
have been placed. The Ramachandran plot obtained from PROCHECK (18)
shows that 99.8% of the residues are in favorable regions and 0.2% of
residues are in disallowed regions. Table I gives the crystallographic data, phasing, and refinement statistics. Figs. 1 and 4-7 were
produced using BOBSCRIPT (19).
Sequence Alignment--
ClustalW (20) was used to perform a
multiple sequence alignment of all of the known human carnitine
acetyltransferases (GenBankTM accession number
P43155), COT (GenBankTM accession number
Q9UKG9), L-CPTI (GenBankTM accession number
P50416), M-CPTI (GenBankTM accession number Q92523), and
CPT II (GenBankTM accession number P23786). Fig. 3
was generated using ALSCRIPT (21) to format the alignment and include
the secondary structural elements of hpCAT. The Dali server (22) was
used to identify structural homologues (optimal pairwise alignment of
protein structures) between hpCAT and other proteins in the Protein
Data Bank.
Structural Superimposition and Substrate Modeling--
The
molecular modeling-interactive graphics program O (16) was used to
superimpose E2p complexed with lipoamide and CoA (Protein Data Bank
code 1EAB) onto domain I of the hpCAT structure and to model the
active site location of carnitine and CoA binding sites. Carnitine was
modeled into the active site of hpCAT by manually docking the chemical
structure of carnitine onto the position of lipoamide and aligning
their reactive The overall structure of hpCAT reveals a monomeric protein with
dimensions of ~75 × 45 × 45 Å (Fig.
1). The tertiary structure consists of 17 helices (H1-H17) and 14 strands (S1-S14), which are arranged into two
equally sized
Structure of Human Carnitine Acetyltransferase
MOLECULAR BASIS FOR FATTY ACYL TRANSFER*
,
,
,
,
Department of Medicinal Chemistry, College
of Pharmacy and § Department of Biochemistry and Molecular
Biology, College of Medicine, University of Florida, Gainesville,
Florida 32610
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
domains. Each domain
is shown to have a partially similar fold to other known but oligomeric
enzymes that are also involved in group-transfer reactions. The unique monomeric arrangement of the two domains constitutes a central narrow
active site tunnel, indicating a likely universal feature for all
members of the carnitine acyltransferase family. Superimposition of the
substrate complex of a related protein, dihydrolipoyl trans-acetylase, reveals that both substrates localize to the active site tunnel of
human carnitine acetyltransferase, suggesting the location of the
ligand binding sites for carnitine and coenzyme A. Most significantly,
this structure provides critical insights into the molecular basis for
fatty acyl chain transfer and a possible common mechanism among a wide
range of acyltransferases utilizing a catalytic dyad.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-oxidation and maintenance of acyl coenzyme A (acyl-CoA)1 pools (1, 2). The
important physiological functions of carnitine are made possible by the
presence of carnitine/acylcarnitine transporters on cellular membranes
and a group of enzymes, the carnitine acyltransferases, which catalyze
the reversible transfer of acyl groups between CoA and carnitine (1, 2)
as shown in Equation 1.
The three known classes of carnitine acyltransferases differ in
their acyl group specificity, subcellular localization, tissue distribution, and physiological function (3-5). Carnitine
acetyltransferase has a substrate preference for short chain acyl-CoAs
and is found in the mitochondrial matrix, the endoplasmic reticulum,
and the peroxisome. Carnitine octanoyltransferase (COT) is
predominantly localized in peroxisomes with a substrate preference for
medium length acyl-CoAs. Carnitine palmitoyltransferases (CPT) are
found both in the outer mitochondrial membrane (CPT I) and the
mitochondrial matrix (CPT II) with a substrate preference for long
chain acyl-CoAs.
(Eq. 1)
-oxidation and the biosynthesis of
fatty acids, depending on the metabolic needs of the cell.
Interestingly, CPT I has an extended N terminus, which contains two
trans-membrane domains, that is not found in the other carnitine
acyltransferases and appears to be important not only in anchoring the
enzyme in the outer mitochondrial membrane but also in modulating
sensitivity of the CPT I isoforms to malonyl-CoA (1). The important
metabolic roles of CPT I make it a potential drug target for diabetes,
coronary heart disease, and other disorders involving abnormal fatty
acid metabolism (6-9).
Crystallographic data, phasing, and refinement statistics of human
peroxisomal carnitine acetyltransferase
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-hydroxyl and sulfur groups, respectively. The
reaction mechanism that we propose for hpCAT involves the formation of
a tetrahedral transition state intermediate (see "Discussion" (Fig.
8). Using the program O (16), this putative tetrahedral intermediate
was manually docked onto the previously modeled positions of CoA and
carnitine, taking into account the bond angles and stereochemistry.
Residues in hpCAT were then identified that may interact with the
negatively charged oxyanion reaction intermediate.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
domains, I (residues 87-385) and II (residues
9-86 and 386-599) (Fig. 2). The domains
are tightly associated with each other by interconnecting loops and
helices that form a central tunnel of ~10-Å diameter that
transverses through the molecule. This tunnel defines a
solvent-accessible surface in the center of the protein, which
constitutes the putative active site for the enzyme. Seventy-six amino
acids accounting for 3400 Å2 (15% of the total surface
area) are buried at the interface between domains I and II (Fig.
1).

View larger version (63K):
[in a new window]
Fig. 1.
Overall structure of human peroxisomal
carnitine acetyltransferase. Ribbon diagram representation depicts
the demarcation of domains I (blue) and II
(orange). The N and C termini are indicated.

View larger version (17K):
[in a new window]
Fig. 2.
Schematic of the topology of domains I and
II. The secondary structural elements are shown with
sequential numbering. Triangles represent strands
S1-S14, and squares represent helices H1-H17.
The hpCAT structure is composed of 39% helix (H1-H17), 13%
-strand (S1-S14), and 48% loops and turns. The most noticeable common feature in domains I and II is an "open-faced" core
five-stranded-mixed
-sheet consisting of three centrally located
parallel
-strands flanked on either side by an anti-parallel
-strand that adopt characteristic left-handed twists. In domain I,
this motif is defined by strands S5, S4, S6, S7, and S8, and in domain
II, this motif is defined by strands S14, S13, S11, S9, and S10. The
-sheet of domain I has a sixth strand, S1, that runs anti-parallel
to strand S8. Domain II provides an additional seventh strand, S12 (looped out between strands S11 and S13 of its five-stranded
-sheet), to the domain I
-sheet that is adjacent and
anti-parallel to strand S1. Therefore, strands S1 and S12 create an
interface between the two domains (Fig. 2).
The N-terminal region of domain II is comprised of four
-helices
(H1-H4). Helices H1 and H2 form an anti-parallel bundle that leads to
an extended structure made up of helices H3 and H4 that cross
over to domain I and contribute part of the floor and front surface of
the active site tunnel. Domain I is defined from residues 87 to 385. Residues 306-320 constitute an anti-parallel pair of strands (S7 and
S8) linked by a type II turn, which forms the rostra lining on the left
side of the active site. An active site histidine (residue 322) is
located on a turn at the end of strand S8 and is positioned in the
center of the active site tunnel. This turn (residues 321-326) leads
to helix H10 that lines the active site tunnel, which is followed by a
loop (located behind the
-sheet in domain I) that forms the upper
lip of an extended surface groove. Helix H11 is next lying on the front
portion of the
-sheet of domain I. A final extended loop after H11
crosses into domain II. This loop leads into helix H12 that runs
parallel with the
-sheet motif of domain II.
-Strands S11-S14
form an intricate hydrogen-bonding network with each other to
facilitate the "flipping out" of strand S12 to align it with strand
S1 in domain I. Four helices, H13-H16, between strands S10 and S11
create a supporting scaffold that positions the domain II
-sheet
open face toward the active site and constitutes the top and right lining of the tunnel. Domain II terminates with helix H17 that also
supports the
-sheet (Figs. 1 and 2).
The structural arrangement of hpCAT appears to be unique for an
acyltransferase, although similar structural elements to portions of
domains I and II have been observed in some oligomeric enzymes that
catalyze similar group-transfer reactions (Fig.
3). The secondary structural elements,
helices H5, H6, and H10 and strands S1, S4, S5, S6, S7, and S8 of
domain I, share structural similarity to the catalytic domain of
dihydrolipoyl trans-acetylase (E2p) (116 C
atoms structurally align
with an r.m.s. deviation of 2.0 Å) (Protein Data Bank code 1EAB) (for
review see Ref. 24). In domain II, helices H12, H13, and H17 and
strands S11, S13, and S14 are structurally similar to portions of
ornithine decarboxylase (ORD) (55 C
atoms structurally align with an
r.m.s. deviation of 2.1 Å) (Protein Data Bank code 1ORD) (for review
see Ref. 25).
|
In addition to structural features, E2p also displays functional
similarity to hpCAT. E2p is a component of the multienzyme pyruvate
dehydrogenase complex and is responsible for the transfer of acetyl
groups between lipoamide and CoA. The catalytically active form of E2p
is a trimer with the active site located in the subunit interface. This
interaction forms an active site channel for CoA and acetyl
lipoamide to bind and is the location of His610, which
serves as a general base for catalysis in E2p (24). A number of studies
have also suggested that the carnitine acyltransferases utilize a
histidine as a general base for catalysis (1). Based on their
structural and functional similarity, the ternary complex of E2p with
both substrates (lipoamide and CoA) was superimposed onto domain I of
the hpCAT structure (see "Experimental Procedures"). The overlay of
these two structures results in the direct superimposition of the
catalytic residue His610 of E2p (23) onto
His322 of hpCAT, which is completely conserved (Fig.
4) and has been previously identified as
essential for enzymatic activity in other carnitine acyltransferases
(1, 28, 29). In hpCAT, this histidine residue is located on a turn at
the end of strand S8 and is positioned in the center of the active site
tunnel (Fig. 6).
|
The location of His322 in the center of the catalytic
tunnel allows access to this essential residue from either side,
suggesting that the binding sites for CoA and carnitine lie on opposite
sides of this tunnel (Fig. 6). Additionally, the superimposition of the
ternary complex of E2p places lipoamide and CoA into the active site
tunnel of hpCAT. The putative location of the separate binding sites
for carnitine (Fig. 7A) and acetyl-CoA (Fig.
7B) were then identified by modeling their positions based
on the locations of lipoamide and CoA using the superimposition of the
E2p complex onto hpCAT. The orientation of the binding pockets allows
each substrate to approach the active site tunnel from opposite sides independently, which is consistent with the rapid equilibrium random
order kinetics proposed for this enzyme (30).
| |
DISCUSSION |
|---|
|
|
|---|
The two domain structural architecture of hpCAT represents a
general model for the structures of other carnitine acyltransferases based on their sequence homology (Fig. 4). There is a 21-31% identity at the amino acid level among the different human carnitine
acyltransferases (1). COT shares the highest homology with hpCAT
followed by CPT II and CPT I. Of note are two consensus sequences that
have been defined for these acyltransferases (23). These are Prosite PS00439 (residues 14-28 in hpCAT) and PS00440 (residues 299-327 in
hpCAT), which form characteristic supersecondary structural motifs of
an extended proline rich region in helix H1 of domain II and strands S7
and S8 of domain I, respectively (Fig.
5). Previously, PS00439 was believed to
be important for carnitine binding (6); however, our structure shows
that this is not the case and instead plays a structural role. On the
other hand, PS00440 is located in the center of the catalytic tunnel
and contains the active site histidine. The regions of highest homology
are clustered in domain II, implying potential locations of common
structural and/or functional significance such as the binding sites for
shared substrates. On the contrary, domain I is more divergent and may contain structural differences for recognition of variable length acyl-CoAs and the physiological regulator malonyl-CoA.
|
Active Site Tunnel and Catalytic Histidine--
The side chain of
His322 of hpCAT adopts an unusual conformation
(
1 =
140°;
2 =
39°) to form an
intraresidue hydrogen bond (2.7 Å) between the imidazole nitrogen N1
and the backbone carbonyl oxygen. In E2p as well as chloramphenicol
acetyltransferase, which also catalyzes an acyl group transfer, a
similar conformation of the active site histidine has been observed and
may represent a conserved structural feature that facilitates catalysis
(23, 26). This unusual angle most probably allows positioning of the
imidazole N3 to align with carnitine, enabling the extraction of a
proton from its primary alcohol. This is consistent with the finding
that the reaction of carnitine acetyltransferase with bromoacetylcarnitine only produces labeled N3 carboxymethyl histidine (27). Additionally, the histidine at this position is highly conserved
among this enzyme family, and the removal of the corresponding homologous residues, His473, His372, and
His327 in rat CPT I, CPT II, and COT, respectively (Fig.
4), has been shown to inactivate these enzymes completely (28, 29).
When His322 was changed to an alanine, a serine, or a
glutamine, the mutant forms of hpCAT were completely inactive,
supporting its catalytic role.2
Catalytic Dyad--
The modeling of carnitine into the active site
reveals a number of residues that may be involved in binding and
catalysis. Most importantly, the N3 nitrogen of the catalytic
His322 is positioned such that it can form a hydrogen bond
and abstract a proton from the
-hydroxyl of carnitine. In addition,
a functionally conserved glutamate, Glu326, interacts with
His322 and appears to be critical for catalysis (Fig.
7A). Carbonyl oxygen 1 (O1) of Glu326 is
positioned 4.03 Å from the N3 nitrogen of His322, whereas
O2 forms a salt bridge with Arg443 (2.78 Å).
This interaction probably further potentiates the activity of
His322 and also stabilizes the positive charge that
would develop after substrate deprotonation. In almost all of the other
members of the family, an aspartate is found at this position, which
could functionally substitute for glutamate. In rat CPT II,
substituting Asp376, which is homologous to
Glu326 in hpCAT, to an alanine produced a completely
inactive protein, illustrating the important role of this negative
charge in catalysis (28). Similar interactions have been observed in
other enzyme active sites that utilize a Ser-His-Asp catalytic triad
including a variety of proteases and lipases as well as acetylcholine
esterase (31, 32). Thus, hpCAT as well as the other carnitine
acyltransferases appear to utilize a His-Glu/Asp catalytic dyad to
carry out catalysis.
Proposed Binding Sites for Carnitine and CoA-- Several conserved residues in carnitine acyltransferases, in particular, Tyr431 and Thr444 of hpCAT, lie within hydrogen-bonding distance of the O1 and O2 of carnitine and appear to interact directly with the carnitine carboxylate group (Fig. 7A). Previously, it has been speculated that a positively charged amino acid forms a salt bridge with the carboxylate group of carnitine in the active site. In bovine COT, the mutation of a conserved arginine to asparagine decreased the binding of carnitine with a greater than 1650-fold increase in the apparent Km(carnitine) (33). In hpCAT, the equivalent residue, Arg497, may fulfill this role by forming an electrostatic interaction with carnitine because it is ~5 Å away. Other naturally occurring and site-directed mutations have been shown to affect carnitine binding (Figs. 4 and 5) (for review see Ref. 1).
The modeled binding site of CoA (Figs. 6
and 7B) reveals that the adenine ring binds to the outer
portion of the catalytic tunnel with the pantothenic arm extending
into the active site. The reactive sulfur
group is positioned for catalysis close to both His322 and
the
-hydroxyl of carnitine. Some highly conserved residues cluster
around this site and may be involved in CoA binding. The positive
charge of Lys398 probably interacts with a negatively
charged phosphate group, whereas Leu142 may bind CoA
through hydrophobic interactions with the methyl groups of the
pantothenic arm. Ser407 and Asp487 are within
hydrogen-bonding distance of the modeled position of CoA and thus may
contribute to CoA binding. Additional residues that have been shown to
be associated with CoA binding and enzymatic activity in hpCAT and
other members of the carnitine acyltransferases cluster in the vicinity
of the active site as shown in Figs. 4 and 5 (for review see Ref.
1).
|
|
Transition State Stabilization-- The structure of hpCAT also allows the identification of another critical class of active site residues, those that contribute to the stabilization of the putative transition state intermediate. In chloramphenicol acetyltransferase, which appears to utilize a similar mechanism as hpCAT for acyl transfer, a serine and a water molecule hydrogen-bonded to a threonine stabilize the transition state (34). Interestingly, a Ser-Thr-Ser motif, which corresponds to Ser531, Thr532, and Ser533 in hpCAT, is completely conserved in this family (Fig. 4). Substitution of the first serine and threonine to an alanine in bovine COT increased the Km toward carnitine by factors of 15 and 80 without significantly changing kcat (35). The replacement of the last serine did not affect the Km for carnitine but reduced kcat by a factor of 10. This finding suggests that the first serine and threonine are involved in carnitine binding, whereas the last serine contributes to transition state stabilization. In the structure of hpCAT, all three of these residues are in the active site close to the modeled position of carnitine. Ser531 approaches the quaternary amine group and Thr532 is near the carboxylate moiety. When a putative transition state analog of carnitine and CoA is modeled into the active site, Ser533 is in the proper orientation to interact with the oxyanion of this intermediate, supporting the role of Ser533 in transition state stabilization, although other residues may also be involved.
Comparison to Other Carnitine Acyltransferases-- Determination of the structure of hpCAT also provides a more realistic model for the study of other members of the acyltransferase family. Recently, Morillas et al. (29, 36) reported a model of the active sites of CPT I and COT based on the structure of enoyl-CoA hydratase, which included ~200 amino acids surrounding the putative catalytic histidine. This model predicts that Ala381 in CPT I (Ala238 in COT) is positioned in the vicinity of the active site histidine. This particular alanine residue is of significance because it is conserved in all of the medium and long chain carnitine acyltransferases (Fig. 4), being replaced by glycine in carnitine acetyltransferase (Gly228). Substitution of this alanine with an aspartate decreased enzymatic activity ~80%. The authors concluded that this result supported their structural model. However, the structure of hpCAT contradicts this proposed model in that Ala381 in CPT I (Ala238 in COT) is predicted to be at the exterior end of domain I and specifically localized on a buried loop between two helices far away from the active site histidine. Thus, the decrease in activity from an aspartate substitution for Ala381 in CPT I (Ala238 in COT) is most probably because of the deleterious effects of a buried negative charge. Therefore, it is clear that the model based on the structure of enoyl-CoA hydratase is limited and may not be relevant to the structures of the carnitine acyltransferases.
When the structure of hpCAT is used to analyze other members of the acyltransferase family, i.e. COT and CPT I and II, it becomes apparent that while the active site region is largely conserved (Fig. 4), significant structural differences are likely to occur on the walls lining the active site tunnel. These differences are predicted as a consequence of amino acid mutations and insertions and deletions within strand S1, a coil region between strands S11 and S12, as well as helix H10 and helix H16 (Figs. 1, 2, and 4). These secondary structural elements may represent the underlying structural basis for selectivity of fatty acid chain length among the carnitine acyltransferase classes. In particular, the most striking difference in the CPT I enzymes is a 13 amino acid insertion between strands S11 and S12 that runs directly through the active site. These changes in CPT I may form a flexible binding pocket that can accommodate long chain acyl groups that hpCAT cannot utilize as substrates.
Structural Basis of Malonyl-CoA Inhibition-- The structure of hpCAT can also be used as a guide to delineate the locations of residues known to be involved in malonyl-CoA inhibition despite the insensitivity of hpCAT to malonyl-CoA (Fig. 4). Studies have identified several conserved residues in the malonyl-CoA-sensitive carnitine acyltransferases. These include His277, His483, and Ala478 of rat L-CPT I and His131, His340, and Ala332 of rat COT (35). Because carnitine acetyltransferase and CPT II lack these residues, this may be the reason why these enzymes are insensitive to malonyl-CoA inhibition. These residues map to helices H5 and H10 of domain I, which are situated on the same face as the solvent-accessible CoA binding surface. Malonyl-CoA possesses additional interactions with CPT I and COT at these residues and thus is able to bind these enzymes preferentially. The binding of malonyl-CoA at this site would prevent the entry of acyl-CoAs into the active site tunnel and thus inhibit enzymatic activity. Furthermore, it is known that both isoforms of CPT I have additional residues localized on the N terminus before two transmembrane domains, which are absent in hpCAT and COT, that influence malonyl-CoA sensitivity and may function by modulating the interaction of malonyl-CoA at this site (37, 38).
Proposed Reaction Mechanism for the Carnitine Acyltransferases-- Despite these structural differences, the carnitine acyltransferases seem to share a common mechanism for trans-esterification. Because chemical modification and site-directed mutagenesis studies have shown that a highly conserved histidine is essential for catalysis in all members of the carnitine/choline acyltransferase enzyme family, it has been suggested that the histidine functions as a general base to catalyze the acyl transfer reaction (1). It has also been postulated that an aspartate may be involved, leading to the suggestion of a catalytic triad-type mechanism, similar to the serine proteases as mentioned previously (28).
Based on the three-dimensional structure of hpCAT, we propose the
following catalytic mechanism for this reaction utilizing a His-Glu/Asp
catalytic-dyad (Fig. 8). In the forward
direction, His322 acts as a general base to deprotonate the
primary alcohol of carnitine, resulting in a positively charged
histidine. Glu326 serves to polarize the histidine to
increase catalytic activity while also stabilizing the positive charge
that develops on the histidine ring. Deprotonation of carnitine
facilitates the nucleophilic attack of the carbonyl carbon of the
thioester bond of acetyl coenzyme A, resulting in the formation of a
tetrahedral intermediate. In the active site Ser533 helps
to stabilize the negatively charged oxyanion intermediate. The
transition state intermediate then collapses to release acetylcarnitine and free coenzyme A. This catalytic mechanism is likely conserved across the carnitine/choline acyltransferase family because of the high
degree of reaction similarity and the nature of these conserved
residues.
|
In summary, the first structure of a carnitine acyltransferase, hpCAT,
provides a number of important structural insights into the catalytic
mechanism of this group of enzymes as well as the putative active site
residues involved in substrate recognition and potential binding sites
for the physiological regulator malonyl-CoA. Additionally, the
structure of hpCAT provides a valuable model for structural
determination of other members of the carnitine acyltransferases as
well as the highly related protein, choline acetyltransferase, which is
the biosynthetic enzyme for the neurotransmitter acetylcholine (39).
The structure of hpCAT also serves as a model for the rational design
of novel and subtype selective drugs for the treatment of heart
disease, diabetes, and other related diseases.
| |
ACKNOWLEDGEMENTS |
|---|
We thank all of the staff at the Cornell High Energy Synchrotron Source for their help and support, especially Chris Heaton, Marian Szebenyi, and Irina Kriksunov for help at the F2 station during x-ray data collection. We also thank David Levitte for providing MAID program and Nathan Bryant for help with the preparation of figures.
| |
FOOTNOTES |
|---|
* This work was supported in part by the University of Florida, College of Medicine start-up funds (to R. M.) and National Institutes of Health Grant R01 GM58197 (to D. H. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The atomic coordinates and the structure factors (code 1NM8) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
¶ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, College of Medicine, P. O. Box 100245, University of Florida, Gainesville, Florida 32610. Tel.: 352-392-5696; Fax: 352-392-3422; E-mail: rmckenna@.ufl.edu.
Published, JBC Papers in Press, January 31, 2003, DOI 10.1074/jbc.M212356200
2 Y. Gu, T. Kukar, and D. Wu, unpublished observations.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: Acyl-CoA, acyl coenzyme A; hpCAT, human peroxisomal carnitine O-acetyltransferase; CPT, carnitine palmitoyltransferase; L-CPT-I, mitochondrial liver isoform of CPT I; M-CPT-I, mitochondrial muscle isoform of CPT I; r.m.s., root mean square; COT, peroxisomal carnitine O-octanoyltransferase; H, helix; S, strand; MAD, multi-wavelength anomalous dispersion; ORD, ornithine decarboxylase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ramsay, R. R., Gandour, R. D., and Van der Leij, F. R. (2001) Biochim. Biophys. Acta 1546, 21-43[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Ramsay, R. R., and Arduini, A. (1993) Arch. Biochem. Biophys. 302, 307-314[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Bieber, L. L. (1988) Annu. Rev. Biochem. 57, 261-283[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Ramsay, R. R. (2000) Biochem. Soc. Trans. 28, 182-186[Medline] [Order article via Infotrieve] |
| 5. | Corti, O., Finocchiaro, G., Rossi, E., Zuffardi, O., and DiDonato, S. (1994) Genomics 23, 94-99[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Finocchiaro, G.,
Taroni, F.,
Rocchi, M.,
Martin, A. L.,
Colombo, I.,
Tarelli, G. T.,
and DiDonato, S.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
661-665 |
| 7. | Anderson, R. C. (1998) Curr. Pharm. Des. 4, 1-16[Medline] [Order article via Infotrieve] |
| 8. | Wagman, A. S., and Nuss, J. M. (2001) Curr. Pharm. Des. 7, 417-450[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Zarain-Herzberg, A., and Rupp, H. (2002) Expert Opin. Investig. Drugs 11, 345-356[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Lian, W., Govindasamy, L., Gu, Y., Kukar, T., Agbandje-McKenna, M., McKenna, R., and Wu, D. (2002) Acta Crystallogr. Sec. D 58, 1193-1194[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Otwinowski, Z., and Minor, W. (1997) Methods Enzymol 276, 307-326 |
| 12. | Miller, R., Gallo, S. M., Khalak, H. G., and Weeks, C. M. (1994) J. Appl. Crystallogr. 27, 613-621[CrossRef] |
| 13. | Sheldrick, G. M. (1998) in Direct Methods for Solving Macromolecular Structures (Fortier, S., ed) , pp. 131-141, Kluwer Academic Publishers, Norwell, MA |
| 14. | Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sec. D 54, 905-921[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Levitt, D. G. (2001) Acta Crystallogr. Sec. D 57, 1013-1019[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sec. A 47, 110-119 |
| 17. | Brunger, A. T. (1992) Nature 355, 472-474[CrossRef] |
| 18. | Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) J. Appl. Crystallogr. 26, 283-291[CrossRef] |
| 19. | Esnouf, R. M. (1997) J. Mol. Graph. Model. 15, 132-134[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Higgins, D.,
Thompson, J.,
Gibson, T.,
Thompson, J. D.,
Higgins, D. G.,
and Gibson, T. J.
(1994)
Nucleic Acids Res.
22,
4673-4680 |
| 21. |
Barton, G. J.
(1993)
Protein Eng.
6,
37-40 |
| 22. | Holm, L., and Sander, C. J. (1993) J. Mol. Biol. 233, 123-128[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Falquet, L.,
Pagni, M.,
Bucher, P.,
Hulo, N.,
Sigrist, C. J.,
Hofmann, K.,
and Bairoch, A.
(2002)
Nucleic Acids Res.
30,
235-238 |
| 24. |
Mattevi, A.,
Obmolova, G.,
Schulze, E.,
Kalk, K. H.,
Westphal, A. H.,
de Kok, A.,
and Hol, W. G.
(1992)
Science
255,
1544 |
| 25. | Momany, C., Ernst, S., Ghosh, R., Chang, N. L., and Hackert, M. L. (1995) J. Mol. Biol. 252, 643-655[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Leslie, A. G. W.,
Moody, P. C. E.,
and Shaw, W. V.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
4133-4137 |
| 27. | Chase, J. F., and Tubbs, P. K. (1970) Biochem. J. 116, 713-720[Medline] [Order article via Infotrieve] |
| 28. |
Brown, N. F.,
Anderson, R. C.,
Caplan, S. L.,
Foster, D. W.,
and McGarry, J. D.
(1994)
J. Biol. Chem.
269,
19157-19162 |
| 29. |
Morillas, M.,
Gomez-Puertas, P.,
Roca, R.,
Serra, D.,
Asins, G.,
Valencia, A.,
and Hegardt, F. G.
(2001)
J. Biol. Chem.
276,
45001-45008 |
| 30. | Chase, J. F., and Tubbs, P. K. (1966) Biochem. J. 99, 32-40[Medline] [Order article via Infotrieve] |
| 31. | Polgar, L. (1992) FEBS Lett. 311, 281-284[CrossRef][Medline] [Order article via Infotrieve] |
| 32. |
Sussman, J. L.,
Harel, M.,
Frolow, F.,
Oefner, C.,
Goldman, A.,
Toker, L.,
and Silman, I.
(1991)
Science
253,
872-879 |
| 33. | Cronin, C. N. (1997) Eur. J. Biochem. 247, 1029-1037[Medline] [Order article via Infotrieve] |
| 34. | Shaw, W. V., and Leslie, A. G. (1991) Annu. Rev. Biophys. Biomol. Struct. 20, 363-386[CrossRef] |
| 35. | Cronin, C. N. (1997) Biochem. Biophys. Res. Commun. 238, 784-789[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Morillas, M.,
Gomez-Puertas, P.,
Rubi, B.,
Clotet, J.,
Arino, J.,
Valencia, A.,
Hegardt, F. G.,
Serra, D.,
and Asins, G.
(2002)
J. Biol. Chem.
277,
11473-11480 |
| 37. |
Brown, N. F.,
Esser, V.,
Foster, D. W.,
and McGarry, J. D.
(1994)
J. Biol. Chem.
269,
26438-26442 |
| 38. |
Jackson, V. N.,
Zammit, V. A.,
and Price, N. T.
(2000)
J. Biol. Chem.
275,
38410-38416 |
| 39. | Wu, D., Schormann, N., Lian, W., Deisenhofer, J., and Hersh, L. B. (1993) J. Neurochem. 61, 1416-1422[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
A. Faye, C. Esnous, N. T. Price, M. A. Onfray, J. Girard, and C. Prip-Buus Rat Liver Carnitine Palmitoyltransferase 1 Forms an Oligomeric Complex within the Outer Mitochondrial Membrane J. Biol. Chem., September 14, 2007; 282(37): 26908 - 26916. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-S. Hsiao, G. Jogl, and L. Tong Crystal Structures of Murine Carnitine Acetyltransferase in Ternary Complexes with Its Substrates J. Biol. Chem., September 22, 2006; 281(38): 28480 - 28487. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Lawrence, K. B. Luther, H. Schindelin, and J. G. Ferry Structural and Functional Studies Suggest a Catalytic Mechanism for the Phosphotransacetylase from Methanosarcina thermophila J. Bacteriol., February 1, 2006; 188(3): 1143 - 1154. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Ma, J. Koepke, S. Panjikar, G. Fritzsch, and J. Stockigt Crystal Structure of Vinorine Synthase, the First Representative of the BAHD Superfamily J. Biol. Chem., April 8, 2005; 280(14): 13576 - 13583. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Jogl, Y.-S. Hsiao, and L. Tong Crystal Structure of Mouse Carnitine Octanoyltransferase and Molecular Determinants of Substrate Selectivity J. Biol. Chem., January 7, 2005; 280(1): 738 - 744. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Cordente, E. Lopez-Vinas, M. I. Vazquez, J. H. Swiegers, I. S. Pretorius, P. Gomez-Puertas, F. G. Hegardt, G. Asins, and D. Serra Redesign of Carnitine Acetyltransferase Specificity by Protein Engineering J. Biol. Chem., August 6, 2004; 279(32): 33899 - 33908. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-S. Hsiao, G. Jogl, and L. Tong Structural and Biochemical Studies of the Substrate Selectivity of Carnitine Acetyltransferase J. Biol. Chem., July 23, 2004; 279(30): 31584 - 31589. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gobin, L. Thuillier, G. Jogl, A. Faye, L. Tong, M. Chi, J.-P. Bonnefont, J. Girard, and C. Prip-Buus Functional and Structural Basis of Carnitine Palmitoyltransferase 1A Deficiency J. Biol. Chem., December 12, 2003; 278(50): 50428 - 50434. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||